Find Funding Opportunities

Find Funding Opportunities

Subscribe to Find Funding OpportunitiesRSS
Filter By:
Returning 227 results

Global Brain and Nervous System Disorders Research Across the Lifespan (R01 Clinical Trials Optional)

PAR
Monday, September 13, 2021
Tuesday, December 12, 2023
R01
PAR-21-311

Funding Opportunity Purpose

This Funding Opportunity Announcement (FOA) encourages grant applications for the conduct of innovative, collaborative research projects between U.S. and low- and middle-income country (LMIC) scientists, on brain and other nervous system function and disorders throughout life, relevant to LMICs (including neurological, mental, behavioral, alcohol and substance use disorders and spanning the full range of science from basic to implementation research). Scientists in upper middle-income LMICs (UMICs) are also eligible to partner directly with scientists at other LMIC institutions with or without out a US partner. Income categories are defined by the World Bank at http://data.worldbank.org/about/country-classifications/country-and-lending-groups.

Global Brain and Nervous System Disorders Research Across the Lifespan (R21 Clinical Trial Optional)

PAR
Monday, September 13, 2021
Tuesday, December 12, 2023
R21
PAR-21-319

Funding Opportunity Purpose

This Funding Opportunity Announcement (FOA) encourages exploratory/developmental research grant applications, proposing the development of innovative, collaborative research projects on brain and other nervous system function and disorders throughout life, relevant to low- and middle-income countries (LMICs). Research on neurological, mental, behavioral, alcohol and substance use disorders may span the full range of science from basic to implementation research. Scientists in the United States (U.S.) or upper-middle income countries (UMICs) are eligible to partner with scientists in LMIC institutions. Scientists in upper middle-income LMICs (UMICs) are also eligible to partner directly with scientists at other LMIC institutions with or without out a US partner. Income categories used are as defined by the World Bank at http://data.worldbank.org/about/country-classifications/country-and-lending-groups. These grants are expected to foster the development of more comprehensive research programs that contribute to the long-term goals of building sustainable research capacity in LMICs to address nervous system development, function and impairment throughout life and to lead to diagnostics, prevention, treatment and implementation strategies. The proposed work may also contribute to developing a base for research networking and evidence-based policy beyond the specific research project.

Administrative Supplements to Promote Diversity in Small Businesses-SBIR/STTR (Admin Supp Clinical Trial Not Allowed)

PA
Friday, September 10, 2021
Workforce Diversity
Tuesday, September 10, 2024
333
PA-21-345

Funding Opportunity Purpose

The National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC) hereby notify Small Business Concerns (SBCs) holding Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) grants that funds are available for administrative supplements to improve the diversity of the research workforce by recruiting and supporting students, postdoctorates, and eligible investigators from groups that have been shown to be nationally underrepresented in health-related research or in the SBIR and STTR programs. This supplement opportunity is also available to PD(s)/PI(s) of research grants who are or become disabled and need additional support to accommodate their disability in order to continue to work on the research project. Administrative supplements must support work within the scope of the original project. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor.

Career Transition Award for NINDS Intramural Clinician-Scientists (K22 Clinical Trial Not Allowed)

PAR
Friday, September 10, 2021
Saturday, July 13, 2024
K22
PAR-21-328
Stephen Korn

Funding Opportunity Purpose

The objective of the NIH Career Transition Award (K22) is to provide support to outstanding basic or clinical investigators to develop their independent research skills through a two phase program: an initial period involving an intramural appointment at the NIH and a final period of support at an extramural institution. This NINDS K22 is specifically designed to facilitate the transition of NINDS intramural neurologist- and neurosurgeon-scientists to independent, academic faculty positions that support clinician-scientists to engage in independently funded scientific research as well as clinical activities.

Career Transition Award for NINDS Intramural Clinician-Scientists (K22 Clinical Trial Required)

PAR
Friday, September 10, 2021
Saturday, July 13, 2024
K22
PAR-21-327

Funding Opportunity Purpose

The objective of the NIH Career Transition Award (K22) is to provide support to outstanding basic or clinical investigators to develop their independent research skills through a two phase program: an initial period involving an intramural appointment at the NIH and a final period of support at an extramural institution. This NINDS K22 is specifically designed to facilitate the transition of NINDS intramural neurologist- and neurosurgeon-scientists to independent, academic faculty positions that support clinician-scientists to engage in independently funded scientific research as well as clinical activities.

Small Vessel VCID Biomarkers Validation Consortium Coordinating Center (U24 Clinical Trial Not Allowed)

RFA
Friday, September 10, 2021
Saturday, November 13, 2021
U24
RFA-NS-22-017

Funding Opportunity Purpose

The purpose of this funding opportunity announcement (FOA) is to have an open competition to support a Coordinating Center for the next phase of the NINDS small vessel vascular contributions to cognitive impairment and dementia (VCID) biomarkers consortium. The original consortium was established under RFA-NS-16-019 and RFA-NS-16-020. The goal of the next phase, under this FOA (Coordinating Center) and RFA-NS-20-005 (sites), is to complete clinical validation of biomarkers initially developed during the first 5-year funding cycle of this program. The Coordinating Center will consist of: (i) an Administrative Core responsible for organizing, coordinating and administratively driving Consortium activities; and (ii) a Data Core that will coordinate, receive, collect, and share data, including de-identified clinical data. The Coordinating Center will provide infrastructure and expertise to drive the consortium administratively and contribute scientifically to validation of biomarkers with specified context of use for future clinical trials, including in large phase III trials, with general and diverse populations, and for generating scientific breakthroughs in our understanding and treatment of VCID.

Detecting Cognitive Impairment, Including Dementia, in Primary Care and Other Everyday Clinical Settings for the General Public and Health Equity, Pragmatic Clinical Trials (U01 Clinical Trial Required)

RFA
Wednesday, September 8, 2021
Thursday, November 11, 2021
U01
RFA-NS-22-009

Funding Opportunity Purpose

The purpose of this funding opportunity announcement (FOA) is to invite applications that address the unmet need to detect cognitive impairment, including dementia, in large and diverse populations seen in primary care across the United States, including in health disparities populations, when a patient, relative, or care provider indicates concern. Proposed clinical paradigms should utilize tools that are simple to use, standardized, and ideally take five minutes or less to administer in a primary care clinical setting.

Emerging Global Leader Award (K43 Independent Clinical Trial Not Allowed)

PAR
Wednesday, September 8, 2021
Tuesday, December 12, 2023
K43
PAR-21-252

Funding Opportunity Purpose

This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA PAR-. The purpose of the Fogarty Emerging Global Leader Award is to provide research support and protected time (three to five years) to an early career research scientist from a low- or middle-income country (LMIC) who holds a junior faculty position at an LMIC academic or research institution, as defined by the World Bank (http://data.worldbank.org/about/country-classifications/country-and-lending-groups , including low-income, lower-middle-income, and upper-middle-income countries). This intensive, mentored research career development experience is expected to lead to an independently funded research career at the LMIC institution or in another LMIC. This Funding Opportunity Announcement (FOA) invites applications from LMIC scientists from any health-related discipline who propose career development activities and a research project that is relevant to the health priorities of their country under the mentorship of LMIC and U.S. mentors.

Emerging Global Leader Award (K43 Independent Clinical Trial Required)

PAR
Wednesday, September 8, 2021
Tuesday, December 12, 2023
K43
PAR-21-251

Funding Opportunity Purpose

This is a reissue of the Emerging Global Leader Program (K43) to align with the clinical trials policy.

Longitudinal Single Cell Characterization of ADRD Postmortem Tissue (R01 Clinical Trial Not Allowed)

PAR
Thursday, September 2, 2021
Wednesday, October 6, 2021
R01
PAR-22-029

Funding Opportunity Purpose

This FOA aims to address three major goals. The first is to utilize single-cell(-nuc) technologies to characterize the changes to cell identity, number, and/or morphology within a defined brain region, the hippocampus, from subjects experiencing mild cognitive impairment (MCI). Specifically, applicants will collect single-cell(-nuc) transcriptomic and epigenetic data from neuronal, glial, or vascular cells using MCI autopsy brains. Next, applicants will propose a data coordination center to collect single-cell(-nuc) omics data generated using diverse tissue sources and various, well-documented tissue preparation techniques from each group in the consortium. This data will be used to identify critical factors for robust and accurate single-cell(-nuc) omics analysis. Finally, this FOA will prompt applicants to coordinate their single-cell(-nuc) data sets with those produced by the BRAIN Initiatives human cell census. The aim is to enable investigators to utilize BRAIN cell census data sets generated from the analysis of healthy human brain and harmonize single-cell(-nuc) data sets from ADRD human brains with the BRAIN Initiative cell type registry.

Pages